NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
NewAmsterdam Pharma Co N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$20.47+0.64 (+3.23%)
Close on Oct 19, 2026
- Market cap
- $2.53B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Operating margin
-1002.9%
Net margin
-905.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -50.6% | -39.7% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -28.3% | |
| Return on assets | – | – | -24.9% | |
| Current ratio | – | – | 7.88 | |
| Interest coverage | – | – | – | |
| Capex to revenue | – | – | 1.1% | |
| Diluted shares | 4M | 4M | 118M |
Where the cash went
Fiscal 2021 to 2025, five years combined
NewAmsterdam Pharma generated $487.74M from operations and spent $1.19M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$487.74M
Used
$1.19M
Capital expenditure$1.19M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-905.7%
×Asset turnover0.03×
×Equity multiplier1.13×
=Return on equity, FY2025-28.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -905.7% | 0.03× | 1.13× | -28.3% |
| FY2024 | -530.3% | 0.08× | 1.16× | -46.2% |
| FY2023 | -1255.8% | 0.03× | 1.15× | -49.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$203.82M
- Cash generatingOperating cash flow above zero-$147.78M
- Return on assets improvedROA up on the prior year-69.6% → -23.6%
- Earnings backed by cashOperating cash flow above net income-$147.78M vs -$203.82M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.08 → 7.88
- No dilutionShare count did not rise94M → 118M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.13 → 0.03